Dimerix Limited
DXB.ASXHealth Care
is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Incorporated in 2004, Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using our innovative
Market Data
$0.182
+0.0%$105.1M
-100000.0x
$-0.027
0.00%
-0.6%
Latest Earnings
Appendix 4D and Half Year Financial Report
26 February 2026
Dimerix reported a net loss of $16.0M for H1 FY2026, widening 24% from $12.9M in the prior period, despite revenue surging 388% to $2.3M driven by licensing income. The biotechnology company achieved significant clinical milestones including full recruitment of >286 patients for its Phase 3 FSGS trial and received orphan drug designation in Japan, while maintaining a solid cash position of $38.5M. Key points: Revenue increased 388% to $2.3M driven by licensing income of $2.1M; Successfully completed full target recruitment of >286 adult patients for ACTION3 Phase 3 clinical trial; Received orphan drug designation for DMX-200 in Japan, adding to existing US, Europe and UK designations
Recent Announcements
Appendix 4D and Half Year Financial Report
Dimerix reported a net loss of $16.0M for H1 FY2026, widening 24% from $12.9M in the prior period, despite revenue surging 388% to $2.3M driven by licensing income. The biotechnology company achieved significant clinical milestones including full recruitment of >286 patients for its Phase 3 FSGS trial and received orphan drug designation in Japan, while maintaining a solid cash position of $38.5M. Key points: Revenue increased 388% to $2.3M driven by licensing income of $2.1M; Successfully completed full target recruitment of >286 adult patients for ACTION3 Phase 3 clinical trial; Received orphan drug designation for DMX-200 in Japan, adding to existing US, Europe and UK designations
Get real-time alerts for DXB
Receive AI-powered earnings summaries and instant notifications when Dimerix Limited releases results.
Register Free